[Form 4] VERACYTE, INC. Insider Trading Activity

Rhea-AI Filing Summary

Annie McGuire, SVP and General Counsel of Veracyte, Inc. (VCYT), reported the sale of 2,283 shares of Veracyte common stock on 09/19/2025 under a pre-established Rule 10b5-1 plan adopted on 09/04/2024. The filing shows a weighted-average sale price of $33.6923 per share, with individual sale prices ranging from $33.50 to $34.00. After the transaction, Ms. McGuire beneficially owned 91,599 shares, reported as direct ownership.

The Form 4 was executed by an attorney-in-fact and explicitly states the sale was made pursuant to the 10b5-1 plan; additional per-price share breakdowns are available on request to the SEC, the issuer, or a shareholder.

Positive

• Transaction disclosed under a formal Rule 10b5-1 plan, indicating pre-established trading instructions
• Complete reporting details provided: transaction date, weighted-average price, price range, and post-transaction beneficial ownership

Negative

• Insider sale of shares which may be perceived by some investors as insider liquidity rather than a vote of confidence
• Per-price share breakdown not included in the filing; only available upon request

Insights

Financial Analyst

TL;DR: Insider sale of 2,283 shares under a 10b5-1 plan at a $33.69 weighted average, leaving 91,599 shares beneficially owned.

The transaction is a routine disposition recorded on Form 4 and executed under a documented 10b5-1 plan dated 09/04/2024, which supports predictable, pre-scheduled trading rather than opportunistic timing. The weighted-average price of $33.6923 and the narrow reported price range ($33.50–$34.00) suggest a single-day execution across a small number of blocks. For investors, the transaction is informative about insider liquidity but does not, by itself, indicate a change in company fundamentals.

Corporate Governance Expert

TL;DR: Proper disclosure and use of a 10b5-1 plan; filing includes required details and a signature by attorney-in-fact.

The Form 4 discloses the reporting person’s officer status, the Rule 10b5-1 plan adoption date, and precise sale metrics, meeting standard governance and disclosure expectations. The statement that detailed per-price share counts are available on request aligns with Form 4 practice. There is no indication of amendment or corrective filing required based on the content provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McGuire Annie

(Last) (First) (Middle)

6000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/19/2025		S(1)		2,283	D	$33.6923(2)	91,599	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 4, 2024.

2. Represents weighted average sales price. Sale prices for the transactions range from $33.50 to $34.00. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

Remarks:

	/s/ Jonathan Wygant, as attorney-in-fact	09/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Veracyte insider Annie McGuire (VCYT) sell on 09/19/2025?

She sold 2,283 shares of Veracyte common stock on 09/19/2025.

At what price did the insider shares sell?

The filing reports a weighted-average sale price of $33.6923, with individual sales ranging from $33.50 to $34.00.

Was the sale part of a pre-approved trading plan?

Yes. The sale was executed pursuant to a Rule 10b5-1 plan adopted on 09/04/2024.

How many Veracyte shares does Annie McGuire beneficially own after the sale?

After the reported transaction she beneficially owned 91,599 shares (reported as direct ownership).

Who signed the Form 4 filing for the reporting person?

The Form 4 was signed by /s/ Jonathan Wygant, as attorney-in-fact on 09/23/2025.